Baker McKenzie advised Bayer on the antitrust and competition aspects of its global exclusive license and collaboration in precision oncology with Kumquat Biosciences, Inc.
Bayer and Kumquat, a clinical-stage biotech company founded by pioneers of the KRAS pathway, announced 12 August that they have entered into an exclusive global license and collaboration to develop and commercialize Kumquat's KRAS G12D inhibitor. Under the agreement, Kumquat is responsible for the initiation and completion of the Phase Ia study, while Bayer will complete development and commercial activities.
Kumquat received US Food and Drug Administration (FDA) clearance of the investigational new drug (IND) for its KRAS G12D inhibitor in July 2025. Under the terms of the agreement, Kumquat will receive up to USD 1.3 billion, including upfront, clinical and commercial milestones, and additional tiered royalties on net sales. Kumquat retains an exclusive option to negotiate for participating in profit-loss sharing in the US.
Led by Creighton Macy, Chair of Baker McKenzie’s Global Antitrust Group, the core Baker McKenzie team advising on the deal included Nicolas Kredel, Jan Kresken, Duk-ki Moon, and Marisa Dieken.
Learn more about the deal on PR Newswire.
Baker McKenzie's globally leading Antitrust & Competition Practice is one of the largest in the world with more than 300 practitioners across 60 offices and 43 countries. Consistently recognized as a global leader, the group handles a broad spectrum of complex competition law matters, including antitrust litigation, antitrust agency investigations, criminal and civil enforcement cases, and merger clearance matters. The team also regularly provides antitrust compliance guidance and training for clients.
Bayer and Kumquat, a clinical-stage biotech company founded by pioneers of the KRAS pathway, announced 12 August that they have entered into an exclusive global license and collaboration to develop and commercialize Kumquat's KRAS G12D inhibitor. Under the agreement, Kumquat is responsible for the initiation and completion of the Phase Ia study, while Bayer will complete development and commercial activities.
Kumquat received US Food and Drug Administration (FDA) clearance of the investigational new drug (IND) for its KRAS G12D inhibitor in July 2025. Under the terms of the agreement, Kumquat will receive up to USD 1.3 billion, including upfront, clinical and commercial milestones, and additional tiered royalties on net sales. Kumquat retains an exclusive option to negotiate for participating in profit-loss sharing in the US.
Led by Creighton Macy, Chair of Baker McKenzie’s Global Antitrust Group, the core Baker McKenzie team advising on the deal included Nicolas Kredel, Jan Kresken, Duk-ki Moon, and Marisa Dieken.
Learn more about the deal on PR Newswire.
Baker McKenzie's globally leading Antitrust & Competition Practice is one of the largest in the world with more than 300 practitioners across 60 offices and 43 countries. Consistently recognized as a global leader, the group handles a broad spectrum of complex competition law matters, including antitrust litigation, antitrust agency investigations, criminal and civil enforcement cases, and merger clearance matters. The team also regularly provides antitrust compliance guidance and training for clients.
Explore Our Newsroom